Evidence map›Paper›PMID 40768643›Full record

ArticleACS chemical neuroscience2025

Design, Synthesis and Biological Evaluation of Chromeno[3,4-

Daniela Malafaia, Natércia F Brás, Anna Sampietro, Inês Quintelas, Pedro Ferreira, Lúcia Melo, Joana Saavedra, Loreto Martinez-Gonzalez, Marisa Pereira, Jessica Sarabando and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Daniela MalafaiaLAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.ORCID 0000-0002-3468-9788
Natércia F BrásLAQV-REQUIMTE, Department of Chemistry and Biochemistry, University of Porto, 4169-007 Porto, Portugal.
Anna SampietroLaboratory of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, 08007 Barcelona, Spain.
Inês QuintelasLAQV-REQUIMTE, Department of Chemistry and Biochemistry, University of Porto, 4169-007 Porto, Portugal.ORCID 0009-0009-5492-152X
Pedro FerreiraLAQV-REQUIMTE, Department of Chemistry and Biochemistry, University of Porto, 4169-007 Porto, Portugal.
Lúcia MeloLAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.
Joana SaavedraMolecular Neurobiology Group, Institute for Health Research and Innovation (i3S), Institute for Molecular and Cellular Biology (IBMC), 4150-180 Porto, Portugal.
Loreto Martinez-GonzalezCentro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28040 Madrid, Spain.
Marisa PereiraInstitute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal.
Jessica SarabandoInstitute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal.
Leo KönigRuprecht-Karls Universität Institut für Pharmazie und Molekulare BiotechnologieIm Neuenheimer Feld 329, D-69120 Heidelberg, Germany.
Isabel CardosoMolecular Neurobiology Group, Institute for Health Research and Innovation (i3S), Institute for Molecular and Cellular Biology (IBMC), 4150-180 Porto, Portugal.ORCID 0000-0003-2472-7055
Daniela RibeiroInstitute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal.
Ana R SoaresInstitute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal.ORCID 0000-0003-4000-7461
Raimon SabatéDepartment of Pharmacy and Pharmaceutical Technology, Department of Physical Chemistry, School of Pharmacy, iUniversity of Barcelona, 08028 Barcelona, Spain.ORCID 0000-0003-3894-2362
Gert FrickerRuprecht-Karls Universität Institut für Pharmazie und Molekulare BiotechnologieIm Neuenheimer Feld 329, D-69120 Heidelberg, Germany.ORCID 0000-0003-3894-961X
Ana MartinezCentro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28040 Madrid, Spain.ORCID 0000-0002-2707-8110
Pedro A FernandesLAQV-REQUIMTE, Department of Chemistry and Biochemistry, University of Porto, 4169-007 Porto, Portugal.ORCID 0000-0003-2748-4722
Artur M S SilvaLAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.ORCID 0000-0003-2861-8286
Hélio M T AlbuquerqueLAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.ORCID 0000-0001-5905-3316

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) remains a complex and unmet medical challenge, requiring innovative approaches to address its multifaceted pathology. In this study, we explored chromeno[3,4-

Indexed as

Alzheimer DiseaseCholinesterase InhibitorsXanthonesAcetylcholinesteraseAmyloid beta-PeptidesAnimalsButyrylcholinesteraseDrug DesignHumansMolecular Docking SimulationPeptide FragmentsAcetylcholinesteraseAmyloid beta-Peptidesamyloid beta-protein (1-42)ButyrylcholinesteraseCholinesterase InhibitorsPeptide FragmentsXanthonesAlzheimer’s diseaseAβ aggregationblood-brain barrier permeabilitychromeno[3,4-b]xanthone cholinesterasesmultifunctional compoundstau protein aggregation

Identifiers

PMID40768643
PMCPMC12818745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.